CHANGMAO BIO (00954) announced its interim results, with a loss attributable to shareholders of 4.932 million yuan, a decrease of 80.88% year-on-year.

CHANGMAO BIO (00954) announced its interim results for the six months ended June 30, 2026, with revenue reaching 290 million yuan, an increase of 6.34% year-on-year; the loss attributable to shareholders of the company was 4.932 million yuan, a decrease of 80.88% year-on-year; loss per share was 0.009 yuan. In the first half of the year, the company recorded a net loss attributable to shareholders of approximately 4.932 million yuan, a significant reduction of about 81% compared to the net loss of 25.79 million yuan in the same period last year, indicating a marked improvement in operational quality and continuing positive fundamentals.